| 09:49 | INDICES: ni Value, ni Growth, Défensif ! |  |
| 01/07 | DOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules |  |
| 01/07 | Pharmaceutical companies still have the upper hand | |
| 30/06 | FDA bittet Impfstoffhersteller um Anpassung auf Omikron-Sublinien |  |
| 30/06 | Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for.. | |
| 30/06 | Hywin Holdings, FactSet Launch Global Health Care Index | |
| 29/06 | NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access | |
| 29/06 | Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i.. | |
| 29/06 | Estas empresas respetan el derecho al aborto en EE.UU. |  |
| 29/06 | Ces sociétés respectent le droit à l'avortement aux États-Unis | |
| 28/06 | MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li.. | |
| 27/06 | Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co.. | |
| 24/06 | Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D.. | |
| 24/06 | J&J: avis favorable de l'UE pour un anti-leucémique | |
| 24/06 | Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr.. | |
| 24/06 | JOHNSON & JOHNSON'S JANSSEN: CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu.. | |
| 24/06 | J&J: confirme son engagement contre les maladies tropicales | |
| 23/06 | JOHNSON & JOHNSON: Renews Commitment to Fight Neglected Tropical Diseases, Investing in B.. | |
| 22/06 | Powell's tall order to reassure investors | |
| 22/06 | ANALYST RECOMMENDATIONS: Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone... | |
| 21/06 | Le roi des céréales Kellogg annonce sa scission en trois entreprises | |
| 21/06 | TRANSCRIPT: Johnson & Johnson - Special Call | |
| 21/06 | Johnson & Johnson Opens Asia-Pacific Satellite Center for Global Health Discovery in Si.. | |
| 21/06 | Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Paci.. | |
| 21/06 | Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Paci.. | |
| 18/06 | AFRIQUE DU SUD: une "bataille difficile" remportée avec la levée des brevets | |
| 17/06 | Standard & Poor's 500 Enters Bear Market Territory as Fed Pivot to Price Stability Fuel.. | |
| 16/06 | Wall Street finit en forte baisse, craint que la Fed n'ait la main trop lourde | |
| 16/06 | TRANSCRIPT: Johnson & Johnson Presents at Goldman Sachs 43rd Annual Global Healthcare Con.. | |
| 16/06 | Federal Government Removes Vaccination Requirements For Domestic And Out-Bound Travel | |
| 15/06 | Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Jo.. | |
| 15/06 | Evotec enters a drug discovery collaboration with Janssen | |
| 15/06 | JOHNSON & JOHNSON VISION ON TRACK FO: ACUVUE® OASYS MAX 1-Day | |
| 15/06 | INSIDER SELL: Johnson & Johnson | |
| 14/06 | Evotec, Johnson & Johnson's Unit Janssen Partner to Discover New Drug Candidates | |
| 14/06 | Evotec kooperiert bei Wirkstoffforschung mit Janssen | |
| 13/06 | Valneva risque de ne pas fournir son vaccin à l'Europe | |
| 10/06 | Johnson & Johnson Unit Janssen Says Early Trial Data Shows Positive Results for Teclist.. | |
| 10/06 | JOHNSON & JOHNSON: New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen .. | |
| 10/06 | JOHNSON & JOHNSON: Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bisp.. | |
| 10/06 | Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results | |
| 10/06 | Genmab Seeks $405 Million in New Arbitration With Janssen | |
| 10/06 | Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen | |
| 08/06 | COVID-19 VACCINES: No Sharing Of Know-How | |
| 08/06 | Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on .. | |
| 08/06 | Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA (erdafitinib.. | |
| 08/06 | Royal Philips - Willem Appelo to succeed Sophie Bechu as Philips Chief Operations Offic.. | |
| 07/06 | Johnson & Johnson Unit Janssen Says Initial Data From Phase 2 Trial of Balversa Shows R.. | |
| 07/06 | Philips Names Willem Appelo COO | |
| 06/06 | Emergent Biosolutions Claims Janssen Pharmaceuticals Breached COVID-19 Vaccine Producti.. | |
| 06/06 | SECTOR UPDATE: Health Care Stocks Slip Amid Losses for Biotechs | |
| 06/06 | Emergent Biosolutions Claims Janssen Pharmaceuticals Breached COVID-19 Vaccine Producti.. | |
| 06/06 | SECTOR UPDATE: Health Care Stocks Edging Higher This Afternoon | |
| 06/06 | SECTOR UPDATE: Health Care | |
| 06/06 | US Stocks Weakening in Midday Trading but Largely Staying on Positive Ground | |
| 06/06 | Top Midday Gainers | |
| 06/06 | Yumanity Therapeutics Shares Soar on Kineta Deal | |
| 06/06 | J&J Risks Up to $420 Million Liability as Emergent Claims COVID-19 Jab Contract Breach | |
| 06/06 | Wall Street Set for Gains, China Tech ADRs Rise on Signs of Easing Regulatory Pressure | |
| 06/06 | J&J: résultats encourageants dans le myélome multiple | |
| 06/06 | Emergent BioSolutions Says Janssen Has Breached Covid Vaccine Contract | |
| 06/06 | The Janssen Pharmaceutical - Phase 3 SHINE Results Show IMBRUVICA (ibrutinib)-Based Com.. | |
| 06/06 | The Janssen Pharmaceutical Companies - Longer-term Data from CARTITUDE-1 Study Demonstr.. | |
| 06/06 | The Janssen Pharmaceutical Companies - Updated Data for Janssen's Bispecific Teclistama.. | |
| 06/06 | Top Premarket Gainers | |
| 06/06 | Yumanity to Sell Neurosciences Candidates, Merge With Kineta | |
| 06/06 | J&J: données mises à jour sur le teclistamab | |
| 06/06 | JOHNSON & JOHNSON: ETHICON LAUNCHES NEXT GENERATION ECHELON™ 3000 STAPLER DESIGNED .. | |
| 06/06 | Johnson & Johnson agreed to acquire Assets of Wholesale Brokerage & Binding and Managin.. | |
| 05/06 | JOHNSON & JOHNSON: Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and.. | |
| 03/06 | Johnson & Johnson's Imbruvica Meets Target in Late-Stage Mantle Cell Lymphoma Trial in .. | |
| 03/06 | JOHNSON & JOHNSON: Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Re.. | |
| 02/06 | Bristol Myers, J&J Arthritis Drugs Cut Covid-19 Deaths in NIH Study | |
| 02/06 | The Janssen Pharmaceutical - New Data Show Patients Treated with First-in-Class TREMFYA.. | |
| 01/06 | J&J: nouvelles données positives autour du Tremfya | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Nederlands (Nederland)
Nederlands (België)
Rapporto
